WP_Unlocking the Future of Mental Health-GMP-Grade Psychedelics

Benuvia Operations, LLC (Benuvia), a U.S.-based pharmaceutical development and manufacturing company specializing in regulated and controlled-substance drug products and active pharmaceutical ingredients (APIs), today announced its role as manufacturing partner supporting Mandara Biopharma Inc.’s (Mandara) filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of a dronabinol oral solution formulation for the treatment of agitation associated with Alzheimer’s disease.

The dronabinol oral solution formulation was developed by Benuvia and licensed to Mandara under an exclusive agreement. Under the collaboration, Benuvia will serve as Mandara’s manufacturing partner for the clinical and potential commercial supply of the product.

How Benuvia Revolutionized Psilocin and Psilocybin Production.

Benuvia and Mikart Announce Strategic Co-Marketing Partnership to Deliver End-to-End Controlled Substance Development and Finished Drug Product Manufacturing Solution

Leading a biotech start-up through a complex regulatory landscape.

Benuvia Innovation Ensures Critical Psychedelic Therapies Can Thrive.

Benuvia’s Scalable Solutions for a Critical API Experiencing a Global Shortage.

Benuvia’s Solution to Scaling Synthetic Delta-9-THC.

Innovative Solutions for Purified Cannabinoids in R&D.

The Critical role of GACP compliance.

How Benuvia’s pharmaceutical-grade APIs and drug products set the benchmark for safety, quality, and reliability.